Opaleye Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Opaleye Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-238,225	Closed	-$848K	–	53
2023 Q3	$848K	Hold	238,225	–	–	0.28%	36
2023 Q2	$1.39M	Hold	238,225	–	–	0.33%	40
2023 Q1	$9M	Buy	238,225 +8,725	+4%	+$286K	2.7%	8
2022 Q4	$6.84M	Buy	229,500 +20,000	+10%	+$605K	2.38%	12
2022 Q3	$7M	Buy	209,500 +3,234	+2%	+$123K	2.89%	10
2022 Q2	$8.25M	Buy	206,266 +48,511	+31%	+$1.88M	3.72%	8
2022 Q1	$8.3M	Buy	157,755 +5,005	+3%	+$252K	2.58%	14
2021 Q4	$8.46M	Buy	152,750 +26,831	+21%	+$1.71M	1.79%	21
2021 Q3	$9.75M	Hold	125,919	–	–	1.82%	17
2021 Q2	$16.3M	Hold	125,919	–	–	2.71%	10
2021 Q1	$20.7M	Hold	125,919	–	–	3.04%	8
2020 Q4	$29.5M	Buy	125,919 +25,247	+25%	+$3.51M	3.85%	7
2020 Q3	$10.4M	Buy	+100,672	New	+$5.39M	2.04%	19
2015 Q2	–	Sell	-61	Closed	-$171K	–	50
2015 Q1	$171K	Buy	+61	New	+$160K	0.08%	37

Other funds holding TCON

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Opaleye Management's TCON Position: Q4 2023 in Review

Opaleye Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2023, closing a stake of 238,225 shares — an estimated $848K sold.

Opaleye Management first reported a position in TCON in Q1 2015 and held it in 14 quarters. The position peaked at $29.5M in Q4 2020. 24 funds tracked by Wall St. Rank hold TCON as of Q4 2023.

Opaleye Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Opaleye Management sold 238,225 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $848K.
Opaleye Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2015 and held it in 14 quarters.
Opaleye Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $29.5M in Q4 2020.
24 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.